Clinical Trial Update: The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin [Phase 4]

View source ↗

Summary

A Phase 4 trial investigating add-on canagliflozin in Type 2 diabetes patients treated with U-500 insulin has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: Joslin Diabetes Center | Conditions: Diabetes, Obesity | Phase 4 | Status: WITHDRAWN